Advertisement

Topics

LONZA Biologics plc Company Profile

21:36 EDT 20th September 2017 | BioPortfolio

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality-minded production. Creative thinking, dedicated staff and sound resources are the strengths that Lonza relies on for further growth. Our people are the key to success – they have extensive expertise in multidisciplinary project management, integrating the wishes and know-how of our customers at every stage.

Location

228 Bath Road
Slough
Berkshire
SL1 4DX
United Kingdom

Contact

Phone: 44 1753 777000
Fax: 44 1753 777001
Email: contact.slough@lonza.com


News Articles [627 Associated News Articles listed on BioPortfolio]

Lonza Buys Swiss Micronization Technology Specialist Micro-Macinazione

Swiss fine chemicals and biologics producer Lonza has acquired Micro-Macinazione, a contract manufacturer providing micronization of active ingredients for the pharmaceutical and fine chemical industr...

Lonza expands in Asia: 8,000L single-use in Singapore, regenerative meds in Japan

Lonza will install four 2,000L single-use bioreactors at its Singapore facility to cater for growing demand for small to mid-volume biologics production.

Lonza has received all regulatory approvals for acquisition of Capsugel

Lonza announced that it has received all regulatory approvals for the proposed acquisition of Capsugel S.A. by Lonza. With all final regulatory approvals in place, Lonza can now complete the transacti...

Lonza and Sanofi to build new multidisciplinary biomanufacturing facility in Switzerland

Lonza Group, a life sciences-driven chemicals company, and French drugmaker Sanofi are to break ground…

Sartorius takes €10m hit on media sales due to Lonza's regulatory woes

Supply chain issues stemming from an FDA warning letter at a facility run by its partner Lonza have dampened Sartorius Stedim Biotech’s first half 2017 results.

Lonza’s $5.5bn Capsugel takeover cleared by regulators

Lonza expects to complete its $5.5bn (€5.2bn) takeover of Capsugel SA in the next few days having secured approval from competition authorities around the world.

Lonza envisions five new plants at Visp for modular manufacturing biz

Lonza has started work on a facility to house its new modular tech-based biomanufacturing service at its site in Visp, Switzerland.

Lonza Expands Support for Researchers with New Endothelial Cell Application Center

Today Lonza announced an endothelial cell application center, which expands Lonza’s support for researchers. This new online suite provides scientists with educational materials and product inf...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Standardized cat pelt [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT PELT AP ACETONE PRECIPITATED

Standardized cat hair [Jubilant HollisterStier LLC]

ALLERGENIC EXTRACT STANDARDIZED CAT HAIR AP Acetone Precipitated

Cinryze [ViroPharma Biologics]

These highlights do not include all the information needed to use CINRYZE™ safely and effectively. See full prescribing information for CINRYZE.CINRYZE™ (C1 Esterase Inhibitor [Human]) For Intrave...

PubMed Articles [112 Associated PubMed Articles listed on BioPortfolio]

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our syste...

Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study.

Biologics are usually licensed according to the "one dose fits all" principle. It is therefore suspected that a significant number of psoriasis patients are overtreated. However, evidence for successf...

Biosimilars: biologics that meet patients' needs and healthcare economics.

Biologics have revolutionized medical care, yet uniform access to these effective medicines remains difficult due to the increasing costs of healthcare. As patent exclusivity on the early biologics wa...

The expanding field of biologics in the management of chronic urticaria.

Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternati...

Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.

There are roughly 5 to 10 million persons infected with human T-lymphotropic virus type 1 (HTLV-1) worldwide, and the safety of treating this population with biologics remains poorly understood.

Clinical Trials [60 Associated Clinical Trials listed on BioPortfolio]

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis

To estimate the real-world effectiveness of approved biologics in subjects with moderate-to-severe plaque psoriasis who are either starting or switching biologic medication.

Companies [237 Associated Companies listed on BioPortfolio]

LONZA Biologics plc

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality...

Lonza Group Ltd

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality...

Lonza Inc.

Basel, 17.05.2006 - Lonza Group announces the acquisition of assets which comprise Larex, Inc.’s Larch Arabinogalactan business. This strategic acquisition includes among other things, intellectual...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

MSD Biologics (UK) Limited

Avecia Biologics was acquired in February 2010 by MSD, the UK subsidiary of Merck & Co Inc, the world’s second largest pharmaceutical company. MSD Billingham is one of the world's leading contract ...

More Information about "LONZA Biologics plc" on BioPortfolio

We have published hundreds of LONZA Biologics plc news stories on BioPortfolio along with dozens of LONZA Biologics plc Clinical Trials and PubMed Articles about LONZA Biologics plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of LONZA Biologics plc Companies in our database. You can also find out about relevant LONZA Biologics plc Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record